TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2893877

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation at a total dose over 2000 cGy (group I)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation at a total dose of 1800 cGy (group II)
Number of subjects: 82
Study: 31658923

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Hybrid intervention integrating CPT with TBI psychoeducation and cognitive rehabilitation (SMART-CPT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: CPT and SMART-CPT (both interventions)
Number of subjects: 100
Study: 29212368

Group type: EXPERIMENTAL
Intervention: Robot-Assisted Laparoscopic Radical Prostatectomy (RALP)
Number of subjects: 3324

Group type: COMPARATOR
Intervention: Open Radical Prostatectomy (ORP)
Number of subjects: 3324
Study: 28629447

Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation
Number of subjects: 0
Study: 26037995

Group type: EXPERIMENTAL
Intervention: Proximal femoral nail antirotation (Group 1)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Dynamic hip screw (Group 2)
Number of subjects: 198
Study: 23240729

Group type: EXPERIMENTAL
Intervention: Daily text messages (TM) for 12 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no TM)
Number of subjects: 20
Study: 21596917

Group type: EXPERIMENTAL
Intervention: High NaCl intake (7.7 meq Na(+)/kg body wt per day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Low NaCl intake (0.7 meq Na(+)/kg body wt per day)
Number of subjects: 8
Study: 18427089

Group type: EXPERIMENTAL
Intervention: Advanced life-support (ALS) phase
Number of subjects: 2867

Group type: COMPARATOR
Intervention: Basic life-support (BLS) phase
Number of subjects: 2867

Group type: EXPERIMENTAL
Intervention: Advanced life-support (ALS) phase (specifically for patients with Glasgow Coma Scale score < 9)
Number of subjects: 2867

Group type: COMPARATOR
Intervention: Basic life-support (BLS) phase (specifically for patients with Glasgow Coma Scale score < 9)
Number of subjects: 2867

Group type: EXPERIMENTAL
Intervention: Advanced life-support (ALS) phase vs Basic life-support (BLS) phase
Number of subjects: 2867
Study: 17298190

Group type: EXPERIMENTAL
Intervention: Multifactorial educational intervention by a pharmacist including disease information, drug therapy, diet education, and active telephone follow-up.
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Multifactorial educational intervention by a pharmacist.
Number of subjects: 134
Study: 15561049

Group type: EXPERIMENTAL
Intervention: LVAD implantation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 0
Study: 11741625

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 17073

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 17073
Study: 9220319

Group type: EXPERIMENTAL
Intervention: Prophylactic low-dose dopamine (2 mg/kg/min) administered 1 hour before IL-2 and discontinued 6-12 hours after maximum IL-2 doses.
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard supportive measures without dopamine (control group).
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Prophylactic low-dose dopamine (2 mg/kg/min).
Number of subjects: 42
Study: 7698967

Group type: EXPERIMENTAL
Intervention: Saphenous vein patch
Number of subjects: 84

Group type: COMPARATOR
Intervention: PTFE patch
Number of subjects: 84
Study: 2439856

Group type: EXPERIMENTAL
Intervention: Empirically devised regimen of forceful spinal manipulation and injections of a dextrose‐glycerine‐phenol ('proliferant') solution
Number of subjects: 81

Group type: COMPARATOR
Intervention: Parallel treatment with less extensive initial local anaesthesia and manipulation, and saline substitution for proliferant
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Visual analogue pain scores and pain diagrams
Number of subjects: 81
Study: 28282777

Group type: COMPARATOR
Intervention: Educational booklet
Number of subjects: 153

Group type: COMPARATOR
Intervention: E-learning
Number of subjects: 153
Study: 27582635

Group type: EXPERIMENTAL
Intervention: Seminar on smoking-related diseases (3 hours) and training in respiratory diseases or thoracic surgery unit (at least 10 months)
Number of subjects: 150

Group type: COMPARATOR
Intervention: No treatment (control group B)
Number of subjects: 150
Study: 25268778

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive containing 20 mcg of ethinyl estradiol and 3 mg of drospirenone
Number of subjects: 56

Group type: COMPARATOR
Intervention: Non-hormonal contraceptive methods
Number of subjects: 56
Study: 24092689

Group type: EXPERIMENTAL
Intervention: Paced breathing with I/E ratio 1:1 at 0.25 Hz
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Paced breathing with I/E ratio 1:2 and 1:3 at 0.25 Hz
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Paced breathing with I/E ratio 1:1, 1:2, and 1:3 at 0.1 Hz
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Paced breathing with I/E ratio 1:1 at 0.1 Hz
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Paced breathing with I/E ratio 1:1, 1:2, and 1:3 at 0.25 Hz
Number of subjects: 14
Study: 21271128

Group type: EXPERIMENTAL
Intervention: Group GT (Threshold)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Group GV (Voldyne)
Number of subjects: 42
Study: 18809731

Group type: EXPERIMENTAL
Intervention: Duloxetine (30 mg b.i.d.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine (100 mg/day)
Number of subjects: 0
Study: 16468960

Group type: EXPERIMENTAL
Intervention: sirolimus-MMF-prednisone
Number of subjects: 165

Group type: COMPARATOR
Intervention: tacrolimus-MMF-prednisone
Number of subjects: 165
Study: 12759471

Group type: EXPERIMENTAL
Intervention: Sickle cell trait (hemoglobin AS)
Number of subjects: 26
Study: 9935203

Group type: EXPERIMENTAL
Intervention: MAGE-3.A1 peptide (3 subcutaneous injections at monthly intervals)
Number of subjects: 39
Study: 7726513

Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam plus amikacin
Number of subjects: 706

Group type: COMPARATOR
Intervention: Ceftazidime plus amikacin
Number of subjects: 706
Study: 2719466

Group type: EXPERIMENTAL
Intervention: Norfloxacin (400 mg every 12 h for 3 days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Aminophylline (6 mg/kg by 30-min intravenous infusion)
Number of subjects: 10
Study: 775615

Group type: EXPERIMENTAL
Intervention: Prednisone treatment
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 99
Study: 31127607

Group type: EXPERIMENTAL
Intervention: Individualized FSH dose (100 IU/d for predicted hyper responders)
Number of subjects: 1032

Group type: COMPARATOR
Intervention: Standard FSH dose (150 IU/d)
Number of subjects: 1032

Group type: EXPERIMENTAL
Intervention: Individualized FSH dose (450, 225, or 100 IU/d based on AFC)
Number of subjects: 1032
Study: 28778281

Group type: EXPERIMENTAL
Intervention: High progesterone levels on the day of hCG administration
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal progesterone levels on the day of hCG administration
Number of subjects: 40
Study: 25662406

Group type: EXPERIMENTAL
Intervention: KRM-20 (20 mg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: KRM-20 (6 mg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: KRM-20 (60 mg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: KRM-20 (16 mg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: KRM-20 (1.6 mg)
Number of subjects: 17
Study: 23407209

Group type: EXPERIMENTAL
Intervention: Positive journalism article about recovery from mental illness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative journalism article about dysfunctional public mental health system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral journalism article about dental hygiene
Number of subjects: 0
Study: 22428491

Group type: EXPERIMENTAL
Intervention: NIRS monitoring with the suggested algorithm (Group A)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: NIRS monitoring without the algorithm (Group B)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 253
Study: 19416257

Group type: EXPERIMENTAL
Intervention: 16% methyl aminolaevulinate (MAL)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 8% methyl aminolaevulinate (MAL)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both 16% and 8% MAL
Number of subjects: 30
Study: 17572615

Group type: EXPERIMENTAL
Intervention: Cervical corpectomy with preserved posterior vertebral wall (CPW)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Conventional corpectomy (CC)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Both CPW and CC
Number of subjects: 178
Study: 15120768

Group type: EXPERIMENTAL
Intervention: Short-term group intervention combining informal multiprofessional teaching with facilitated peer exchange and support, delivered over 6 sessions of 90 minutes per week.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (comparison group)
Number of subjects: 0
Study: 11267856

Group type: COMPARATOR
Intervention: Split-course irradiation (two courses of 20 Gy in five fractions of 4 Gy, separated by a rest of 2 weeks)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) plus split-course irradiation (3-4 days before each of the two courses of radiotherapy, repeated every 3-4 weeks, for a total of six cycles)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Split-course irradiation
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) plus split-course irradiation
Number of subjects: 211
Study: 9885179

Group type: EXPERIMENTAL
Intervention: 50 mg acetylsalicylic acid (ASA)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 50 mg acetylsalicylic acid (ASA) + 2 x 200 mg dipyridamole
Number of subjects: 42

Group type: COMPARATOR
Intervention: Phenprocoumon
Number of subjects: 42
Study: 8279943

Group type: EXPERIMENTAL
Intervention: PAF antagonist Ro 24‐4736, 10 mg orally
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3569338

Group type: EXPERIMENTAL
Intervention: 100 mCi 131I
Number of subjects: 40

Group type: COMPARATOR
Intervention: 30 mCi 131I
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 300 mCi 131I
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 150 mCi 131I (therapeutic dose for all patients)
Number of subjects: 40
Study: 31369470

Group type: EXPERIMENTAL
Intervention: Normal Tone test condition (no alterations to lexical tones)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Flat Tone test condition (all tones changed to tone 1)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Random Tone test condition (random assignment of tones)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Cognitive function
Number of subjects: 32
Study: 29784451

Group type: EXPERIMENTAL
Intervention: 60 Gy over 11 weeks with concomitant 5FU - hydroxyurea (VP-arm)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 60 Gy (1.2 Gy twice daily) over 5 weeks with cetuximab (HFR-arm)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Toxicities and disease-free survival (DFS)
Number of subjects: 53
Study: 27131588

Group type: EXPERIMENTAL
Intervention: Evidence-based laparoscopy curriculum
Number of subjects: 27

Group type: COMPARATOR
Intervention: Conventional residency training
Number of subjects: 27
Study: 23349402

Group type: EXPERIMENTAL
Intervention: New Perspectives
Number of subjects: 59

Group type: COMPARATOR
Intervention: Transforming Your Life
Number of subjects: 59
Study: 22507493

Group type: EXPERIMENTAL
Intervention: Low-dose abdominal computed tomography (LDCT)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Plain abdominal radiography (AR)
Number of subjects: 108
Study: 20624483

Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 18407467

Group type: EXPERIMENTAL
Intervention: COMT Val158Met genotype
Number of subjects: 130
Study: 18652154

Group type: EXPERIMENTAL
Intervention: Adenoidectomy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (children free of otolaryngological problems)
Number of subjects: 30
Study: 15185427

Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (11 microg twice weekly)
Number of subjects: 9
Study: 11714065

Group type: EXPERIMENTAL
Intervention: Terbinafine 1% cream, applied once daily for 7 days
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo cream, applied once daily for 7 days
Number of subjects: 117
Study: 9240592

Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 102

Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 102
Study: 8237866

Group type: EXPERIMENTAL
Intervention: Two FeSO4 tablets (100 mg Fe) daily
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: One GDS capsule (50 mg Fe) daily
Number of subjects: 376

Group type: COMPARATOR
Intervention: No iron supplement
Number of subjects: 376
Study: 2897260

Group type: EXPERIMENTAL
Intervention: GHRH 1-29 (1 microgram/kg i.v.) in anorexia nervosa patients
Number of subjects: 14

Group type: COMPARATOR
Intervention: GHRH 1-29 (1 microgram/kg i.v.) in normal controls
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: GHRH 1-29 (1 microgram/kg i.v.) in tamoxifen-pretreated women
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: GHRH administration in all groups
Number of subjects: 14

Group type: COMPARATOR
Intervention: GHRH administration in untreated control women
Number of subjects: 14
Study: 31277060

Group type: COMPARATOR
Intervention: Conventional spine MRI
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Combined conventional MRI and ZOOM‐EPI DTI
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: ZOOM‐EPI DTI
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Tractography
Number of subjects: 38
Study: 27868466

Group type: EXPERIMENTAL
Intervention: Immunoxel honey lozenges
Number of subjects: 269

Group type: COMPARATOR
Intervention: Placebo lozenges
Number of subjects: 269
Study: 26012780

Group type: EXPERIMENTAL
Intervention: Augmentation with Staphylococcus epidermidis applied to the face twice per week for four weeks
Number of subjects: 0
Study: 24265159

Group type: EXPERIMENTAL
Intervention: Evening administration of MTX/6MP
Number of subjects: 532

Group type: COMPARATOR
Intervention: Morning administration of MTX/6MP
Number of subjects: 532
Study: 21750293

Group type: EXPERIMENTAL
Intervention: BAL-directed therapy (n = 84)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Standard therapy (n = 86)
Number of subjects: 170
Study: 19008239

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 71
Study: 18062758

Group type: EXPERIMENTAL
Intervention: Manual vacuum aspiration (MVA)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Electric vacuum aspiration (EVA)
Number of subjects: 157
Study: 15041599

Group type: EXPERIMENTAL
Intervention: Intraarticular sufentanil 10 microg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sufentanil plus methylprednisolone 10 microg plus 40 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intraarticular saline (control)
Number of subjects: 60
Study: 11149478

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1 g daily)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Low calorie diet without calcium supplementation
Number of subjects: 62
Study: 9136944

Group type: EXPERIMENTAL
Intervention: Interferon alpha
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: Busulphan
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: Risk profile (Sokal)
Number of subjects: 490

Group type: COMPARATOR
Intervention: Treatment groups
Number of subjects: 490
Study: 8267186

Group type: EXPERIMENTAL
Intervention: Pirenzepine 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ranitidine 50 mg
Number of subjects: 0
Study: 3318990

Group type: EXPERIMENTAL
Intervention: Real ECT
Number of subjects: 22

Group type: COMPARATOR
Intervention: Simulated ECT
Number of subjects: 22
Study: 30987432

Group type: EXPERIMENTAL
Intervention: Nicorandil (10 mg 3 times/d and hydration)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control (hydration only)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 250
Study: 29696915

Group type: COMPARATOR
Intervention: Medication group (Adalat 30 mg at 7 am daily for 6 weeks)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: No.1 acupuncture group (acupuncture technique for activating blood circulation, eliminating wind and regulating the liver and spleen, in addition to medication)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: No.2 acupuncture group (additional acupuncture at Fengchi (GB 20) and Neck‐Jiaji (EX‐B 2) on top of No.1 acupuncture group treatment)
Number of subjects: 90
Study: 27761024

Group type: EXPERIMENTAL
Intervention: Glucose consumption
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disinhibited eating (characterized by reduced HRV)
Number of subjects: 0
Study: 24914549

Group type: EXPERIMENTAL
Intervention: Citalopram (30 mg/day)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study: 22352475

Group type: EXPERIMENTAL
Intervention: Multi-electrode stimulation with matched pulsing electrodes
Number of subjects: 7
Study: 19933778

Group type: EXPERIMENTAL
Intervention: Conditional cash transfer programme (Oportunidades)
Number of subjects: 979
Study: 18442899

Group type: EXPERIMENTAL
Intervention: KNAVE‐II
Number of subjects: 120

Group type: COMPARATOR
Intervention: Paper charts
Number of subjects: 120

Group type: COMPARATOR
Intervention: ESS
Number of subjects: 120
Study: 16160396

Group type: EXPERIMENTAL
Intervention: 3D-MRA
Number of subjects: 32
Study: 12145715

Group type: EXPERIMENTAL
Intervention: Mupirocin nasal ointment applied twice daily from admission to surgery
Number of subjects: 614

Group type: COMPARATOR
Intervention: Placebo nasal ointment applied twice daily from admission to surgery
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Mupirocin nasal ointment
Number of subjects: 614

Group type: COMPARATOR
Intervention: Placebo nasal ointment
Number of subjects: 614
Study: 9990598

Group type: EXPERIMENTAL
Intervention: Pharmacological therapy (i.v. procainamide)
Number of subjects: 68

Group type: COMPARATOR
Intervention: DC shock
Number of subjects: 68
Study: 8520806

Group type: EXPERIMENTAL
Intervention: Diclofenac dispersible 46.5 mg (equivalent to 50 mg of diclofenac sodium)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 2315431

Group type: EXPERIMENTAL
Intervention: Sibutramine HCl (15 mg twice daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sibutramine HCl (single dose of 12.5 or 50 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sibutramine HCl (5‐20 mg once daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6968220

Group type: EXPERIMENTAL
Intervention: Indometacin (200 mg daily)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Acemetacin (200 mg daily)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Acemetacin (240 mg daily)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Wash-out period
Number of subjects: 35
Study: 31533156

Group type: EXPERIMENTAL
Intervention: Whole-body electrostimulation (WB-EMS) with different electrical parameters
Number of subjects: 22

Group type: COMPARATOR
Intervention: Resistance circuit training (control)
Number of subjects: 22
Study: 28853971

Group type: EXPERIMENTAL
Intervention: Stepwise interactive education intervention
Number of subjects: 160

Group type: COMPARATOR
Intervention: General vaccination leaflet (Control)
Number of subjects: 160
Study: 25576262

Group type: EXPERIMENTAL
Intervention: Water restriction trials
Number of subjects: 19

Group type: COMPARATOR
Intervention: Water intake trials
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Post-exercise rehydration
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Overall comparison of Tosm and Posm
Number of subjects: 19
Study: 23711804

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg
Number of subjects: 15526

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 5 mg
Number of subjects: 15526

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15526
Study: 21840055

Group type: EXPERIMENTAL
Intervention: Statin therapy (specific statins not detailed)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Nonadherence to medication
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Beliefs about medicines (assessed using BMQ-G)
Number of subjects: 185
Study: 19675488

Group type: EXPERIMENTAL
Intervention: Estimation group (Group A)
Number of subjects: 4640

Group type: COMPARATOR
Intervention: Validation group (Group B)
Number of subjects: 4640
Study: 17585026

Group type: EXPERIMENTAL
Intervention: Sodium acetate (NaAc)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sodium bicarbonate (NaHCO3)
Number of subjects: 8
Study: 14651448

Group type: EXPERIMENTAL
Intervention: Person-centered planning processes
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional interdisciplinary service planning (ISP)
Number of subjects: 20
Study: 11878726

Group type: EXPERIMENTAL
Intervention: Ropivacaine 150 mg (7.5 mg ml(‐1))
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Ropivacaine 100 mg (5 mg ml(‐1))
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Ropivacaine 200 mg (10 mg ml(‐1))
Number of subjects: 72

Group type: COMPARATOR
Intervention: Bupivacaine 100 mg (5 mg ml(‐1))
Number of subjects: 72
Study: 9751469

Group type: EXPERIMENTAL
Intervention: Static shoulder rotator endurance training
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Dynamic shoulder rotator endurance training
Number of subjects: 37
Study: 7656632

Group type: EXPERIMENTAL
Intervention: BiPAP system
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: BiPAP-NRV
Number of subjects: 7

Group type: COMPARATOR
Intervention: CIPS (conventional intensive care ventilator)
Number of subjects: 7
Study: 2744356

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pentagastrin injection
Number of subjects: 30
Study: 333606

Group type: EXPERIMENTAL
Intervention: Preoperative and intraoperative antibiotics
Number of subjects: 1591

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1591